Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
Fulcrum Therapeutics announced discontinuation of its pociredir program for sickle cell disease after receiving FDA feedback that raised concerns about the risk of secondary malignancies linked to the drug's target, influenced by a related drug's market withdrawal. Despite positive clinical signals, the FDA sees no viable regulatory path forward. F…